Table 1

Vaccines administered, autoimmune diagnoses, immunosuppressive regimens and perivaccination management with serial antispike antibody responses

Age/sexDiagnosisImmunosuppressionInitial vaccine seriesMeds held or modified preinitial VaccinePre-AD1 antibody U/mL*Additional vaccinesPostAD1 antibody U/mL*PostAD2 antibody U/mL*Therapy held periAD†
62FMyositisMycophenolate‡
Prednisone
PfizerNoNegative§AD1: Pfizer
AD2: Pfizer
<0.4No
56FMucous membrane pemphigoidMycophenolate‡PfizerNo<0.4AD1: J&J
AD2: Moderna
<0.8<0.4No
67FSystemic sclerosisMycophenolate‡PfizerNo<0.4AD1: Pfizer
AD2: Pfizer
<0.42.1Yes
73MMyasthenia gravisMycophenolate‡
Prednisone
ModernaNo<0.4AD1: Pfizer
AD2: Pfizer
21.8
44FInflammatory arthritis¶Abatacept
Hydroxychloroquine
Methotrexate
Prednisone
PfizerNo<0.4AD1:Pfizer
AD2: J&J
<0.427.1Yes
55MInflammatory arthritis¶Infliximab Mycophenolate‡PfizerNoNegative§AD1: Pfizer
AD2: Pfizer
<0.846.5Yes
64FMyositisMycophenolate‡PfizerNoNegative§AD1: Pfizer
AD2: Pfizer
38.1120.9Yes
53FInflammatory arthritis¶Adalimumab
Mycophenolate‡
Prednisone
PfizerNo<0.4AD1: Moderna
AD2: Moderna
229134No
55MSarcoidosisInfliximab Mycophenolate‡
Prednisone
PfizerNo<0.4AD1: Moderna
AD2: Moderna
2.401276Yes
40FInflammatory bowel diseaseAdalimumab
Hydroxychloroquine
Methotrexate
PfizerNo178.4AD1: Moderna
AD2: Pfizer
601.21750No
49FOverlap CT disease**Belimumab
Methotrexate
Prednisone
PfizerNo<0.4AD1: Pfizer
AD2: Pfizer
16.4>2500
68FProliferative nephritisMycophenolate‡
Prednisone
ModernaNo<0.4AD1: J&J
AD2: Moderna
714>2500
53FSjὅgren’s syndromeAzathioprineJ&JNo<0.4AD1: Pfizer
AD2: Pfizer
>250>2500Yes
55FMinimal change diseaseMycophenolate‡J&JNo<0.4AD1: Moderna
AD2: Moderna
>2500>2500No
74MMyositisMycophenolate‡PfizerNoNegative§AD1: Moderna
AD2: Moderna
>2500>2500Yes
42FOverlap CT disease**Hydroxychloroquine Mycophenolate‡PfizerNo<0.4AD1: Pfizer
AD2: Pfizer
>2500Yes
65FInflammatory arthritisAbataceptJ&JNoNegative§AD1: Pfizer
AD2: Pfizer
>2500Yes
52MOverlap CT disease**Hydroxychloroquine Mycophenolate‡J&JNo18.6AD1: Pfizer
AD2: Pfizer
>2500>2500Yes
  • - denotes missing data.

  • *Roche Elecsys anti-RBD pan-Ig≥0.8 units/mL is considered positive (upper ceiling expanded from>250 to >2500 U/mL per manufacturer).

  • †Pre-AD1 median number of doses held for mycophenolate 6, 23 doses of azathioprine held by one patient, and two abatacept infusion held by one patient. Pre-AD2 median number (IQR) of doses of mycophenolate 14 (10–14), 23 doses of azathioprine and 2 abatacept infusion held by one patient.

  • ‡Mycophenolate includes mycophenolic acid and mycophenolate mofetil.

  • §Self-reported values.

  • ¶Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis.

  • **Denotes a combination of two or more defined rheumatic diagnoses.

  • AD, additional dose; J&J, Johnson and Johnson; RBD, receptor binding domain.